Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01892293 · OUTCOME

Peak Persistence of Modified T-cells in the Peripheral Blood

CT Antigen TCR-Engineered T Cells for Myeloma · Source last updated 2019-01-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
copies per μg of DNA
Interval / dispersion
Full Range
Time frame
Days 1, 3, 5, 8, 15, 22, 29, 43, 101, 130 181, every 3 months thereafter

What was measured

Measurement of NY-ESO-1ᶜ²⁵⁹T cells in blood (copies of WPRE per µg of genomic PBMC DNA)

Analysis population: Participants who received cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T with persistence data

Groups in this outcome

NY-ESO-1ᶜ²⁵⁹T Cells Administered IV

Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NY-ESO-1ᶜ²⁵⁹T Cells Administered IV2

Reported measurements

Source class 1
Values in copies per μg of DNA · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
NY-ESO-1ᶜ²⁵⁹T Cells Administered IV29,179Not reported447953,879Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4479
        upper Limit
        53,879
        value
        29,179
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
Measurement of NY-ESO-1ᶜ²⁵⁹T cells in blood (copies of WPRE per µg of genomic PBMC DNA)
dispersion Type
Full Range
groups
  1. description
    Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)
    id
    OG000
    title
    NY-ESO-1ᶜ²⁵⁹T Cells Administered IV
param Type
MEAN
population Description
Participants who received cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T with persistence data
reporting Status
POSTED
time Frame
Days 1, 3, 5, 8, 15, 22, 29, 43, 101, 130 181, every 3 months thereafter
title
Peak Persistence of Modified T-cells in the Peripheral Blood
type
SECONDARY
unit Of Measure
copies per μg of DNA

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice